BrightPath Biotherapeutics Co., Ltd. reported consolidated earnings results for the year first quarter ended June 30, 2018. For the quarter, on consolidated basis, the company reported net sales of JPY 122 million against JPY 90 million a year ago. Operating loss was JPY 397 million against JPY 262 million a year ago. Ordinary loss was JPY 399 million against JPY 262 million a year ago. Loss attributable to owners of parent was JPY 583 million or JPY 13.94 per share against JPY 263 million or JPY 7.08 per share a year ago. Loss before income tax was JPY 581.925 million against JPY 262.140 million a year ago.

For the year ending March 31, 2019, the company expects net sales of JPY 150 million, operating loss of JPY 2,200 million, ordinary loss of JPY 2,200 million and net loss attributable to owners of parent of JPY 2,200 million or JPY 52.59 per share.